(Q28166395)

English

Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies

scientific article (publication date: December 2003)

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies (English)

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

Christopher B. Granger

3

object named as

Christopher B Granger

0 references

Kenneth W Mahaffey

2

object named as

Kenneth W Mahaffey

0 references

4

object named as

Matthew T Roe

0 references

author name string

Richard E Waters

1

0 references

language of work or name

0 references

publication date

December 2003

0 references

American Heart Journal

0 references

146

0 references

6

0 references

958-68

0 references

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A comparison of reteplase with alteplase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

The search for replacements for unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900439-3

7 January 2021

Identifiers

10.1016/S0002-8703(03)00439-3

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28166395&oldid=1371307088"